Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 792698, 7 pages
http://dx.doi.org/10.1155/2013/792698
Research Article

rHuEPO Hyporesponsiveness and Related High Dosages Are Associated with Hyperviscosity in Maintenance Hemodialysis Patients

1Department of Nephrology, Baskent University Medical School, 06490 Ankara, Turkey
2Department of Hematology, Baskent University Medical School, 06490 Ankara, Turkey
3Department of Internal Medicine, Baskent University Medical School, 06490 Ankara, Turkey
4Department of Hematology, Ankara University Medical School, 06490 Ankara, Turkey

Received 30 May 2013; Accepted 18 August 2013

Academic Editors: R. Ando, F. Hinoshita, and R. Sakai

Copyright © 2013 Mehtap Erkmen Uyar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Yonem, B. Cakir, O. Azal et al., “Blood viscosity and its relationship with plasma fibrinogen and cholesterol levels in young obese patients,” Turkish Medical Journal, vol. 6, no. 6, pp. 295–298, 1999. View at Google Scholar
  2. F. Jung, G. Pindur, and H. Kiesewetter, “Plasma viscosity dependence on proteins and lipoprotiens: results of the Aachen study,” Clinical Hemorheology, vol. 12, no. 4, pp. 557–571, 1992. View at Google Scholar · View at Scopus
  3. W. Koenig, M. Sund, B. Filipiak, A. Döring, H. Löwel, and E. Ernst, “Plasma viscosity and the risk of coronary heart disease: results from the MONICA-Augsburg cohort study, 1984 to 1992,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, pp. 768–772, 1998. View at Google Scholar · View at Scopus
  4. D. Molino, D. De Lucia, and N. G. De Santo, “Coagulation disorders in uremia,” Seminars in Nephrology, vol. 26, no. 1, pp. 46–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Ambühl, R. P. Wüthrich, W. Korte, L. Schmid, and R. Krapf, “Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation,” Nephrology Dialysis Transplantation, vol. 12, no. 11, pp. 2355–2364, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-C. Gris, B. Branger, F. Vécina, B. Al Sabadani, J. Fourcade, and J.-F. Schved, “Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients,” Kidney International, vol. 46, no. 3, pp. 807–813, 1994. View at Google Scholar · View at Scopus
  7. N. Ferrara and S. Bunting, “Vascular endothelial growth factor, a specific regulator of angiogenesis,” Current Opinion in Nephrology and Hypertension, vol. 5, no. 1, pp. 35–44, 1996. View at Google Scholar · View at Scopus
  8. A. Aguilera, M. A. Bajo, J. J. Díez et al., “Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients,” Advances in Peritoneal Dialysis, vol. 18, pp. 200–205, 2002. View at Google Scholar · View at Scopus
  9. G. D. O. Lowe, “Blood viscosity and cardiovascular disease,” Thrombosis and Haemostasis, vol. 67, no. 5, pp. 494–498, 1992. View at Google Scholar · View at Scopus
  10. D. E. McMillan, “Physical factors important in the development of atherosclerosis in diabetes,” Diabetes, vol. 30, no. 2, pp. 97–104, 1981. View at Google Scholar · View at Scopus
  11. A. B. Irish and F. R. Green, “Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype,” Nephrology Dialysis Transplantation, vol. 13, no. 3, pp. 679–684, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Stasko, S. Funiak, S. Funiakova et al., “Erythropoietin, thrombomodulin, factor von Willebrand and hemodialysis,” Revista Iberoamericana de Trombosis y Hemostasia, vol. 8, article 134, 1995. View at Google Scholar
  13. J. J. J. M. Wirtz, J. W. J. Van Esser, K. Hamulyak, K. M. L. Leunissen, and J. P. Van Hooff, “The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients,” Clinical Nephrology, vol. 38, no. 5, pp. 277–282, 1992. View at Google Scholar · View at Scopus
  14. B. Jaar, A. Denis, B. Viron et al., “Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation,” American Journal of Nephrology, vol. 17, no. 5, pp. 399–405, 1997. View at Google Scholar · View at Scopus
  15. T. Arinsoy, O. Ozdemir, N. Arik et al., “Recombinant human erythropoietin treatment may induce antithrombin-III depletion,” Nephron, vol. 62, no. 4, pp. 480–481, 1992. View at Google Scholar · View at Scopus
  16. C.-H. Ho, “White blood cell and platelet counts could affect whole blood viscosity,” Journal of the Chinese Medical Association, vol. 67, no. 8, pp. 394–397, 2004. View at Google Scholar · View at Scopus
  17. M. R. W. Langenfeld, R. Veelken, H. P. Schobel, A. Friedrich, and R. E. Schmieder, “Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension?” Nephrology Dialysis Transplantation, vol. 12, no. 6, pp. 1155–1160, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. I. C. MacDougall, M. E. Davies, I. Hallett, D. L. Cochlin, R. D. Hutton, and G. A. J. D. Coles Williams, “Coagulation studies and fistula blood flow during Erythropoitin therapy in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 6, no. 11, pp. 862–867, 1991. View at Google Scholar · View at Scopus
  19. A. E. G. Raine, “Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy,” The Lancet, vol. 1, no. 8577, pp. 97–99, 1988. View at Google Scholar · View at Scopus
  20. G. R. Dy, E. J. Bloom, G. K. Ijelu, G. W. Merritts, M. S. Kramer, and R. M. Raja, “Effect of recombinant human erythropoietin on vascular access,” ASAIO Transactions, vol. 37, no. 3, pp. M274–M275, 1991. View at Google Scholar · View at Scopus
  21. N. Muirhead, “Erythropoietin is a cause of access thrombosis,” Seminars in Dialysis, vol. 6, pp. 184–188, 1993. View at Google Scholar
  22. B. D. Bradbury, M. D. Danese, M. Gleeson, and C. W. Critchlow, “Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 3, pp. 630–637, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. D. Solomon, H. Uno, E. F. Lewis et al., “Erythropoietic response and outcomes in kidney disease and type 2 diabetes,” The New England Journal of Medicine, vol. 363, no. 12, pp. 1146–1155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. E. F. Unger, A. M. Thompson, M. J. Blank, and R. Temple, “Erythropoiesis-stimulating agents—time for a reevaluation,” The New England Journal of Medicine, vol. 362, no. 3, pp. 189–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. D. Solomon, H. Uno, E. F. Lewis et al., “Erythropoietic response and outcomes in kidney disease and type 2 diabetes. Trial to Reduce Cardiovascular Events with Aranesp Therapy [TREAT] Investigators,” The New England Journal of Medicine, vol. 363, no. 12, pp. 1146–1155, 2010. View at Google Scholar
  26. K. R. Kensey, “The mechanistic relationships between hemorheological characteristics and cardiovascular disease,” Current Medical Research and Opinion, vol. 19, no. 7, pp. 587–596, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Lee, P. I. Mowbray, G. D. O. Lowe, A. Rumley, F. G. R. Fowkes, and P. L. Allan, “Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study,” Circulation, vol. 97, no. 15, pp. 1467–1473, 1998. View at Google Scholar · View at Scopus
  28. J. W. G. Yarnell, I. A. Baker, P. M. Sweetnam et al., “Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies,” Circulation, vol. 83, no. 3, pp. 836–844, 1991. View at Google Scholar · View at Scopus
  29. L. Bogar, “Hemorheology and hypertension: not “chicken or egg” but two chickens from similar eggs,” Clinical Hemorheology and Microcirculation, vol. 26, no. 2, pp. 81–83, 2002. View at Google Scholar · View at Scopus
  30. M. W. Rampling, “Haemorheological disturbances in hypertension: the influence of diabetes and smoking,” Clinical Hemorheology and Microcirculation, vol. 21, no. 3-4, pp. 183–187, 1999. View at Google Scholar · View at Scopus
  31. G. De Simone, R. B. Devereux, S. Chien, M. H. Alderman, S. A. Atlas, and J. H. Laragh, “Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults,” Circulation, vol. 81, no. 1, pp. 107–117, 1990. View at Google Scholar · View at Scopus
  32. N. Dikmenoglu, “Kardiyovasküler hastalıklarda sigara ve kolesterol kadar önemli bir risk faktörü: kan akıskanlıgı,” Hacettepe Tıp Dergisi, vol. 37, pp. 93–97, 2006. View at Google Scholar
  33. K. Ateş, G. Nergizoǧlu, K. Keven et al., “Effect of fluid and sodium removal on mortality in peritoneal dialysis patients,” Kidney International, vol. 60, no. 2, pp. 767–776, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. A. H. Tzamaloukas, M. C. Saddler, G. H. Murata et al., “Symptomatic fluid retention in patients on continuous peritoneal dialysis,” Journal of the American Society of Nephrology, vol. 6, no. 2, pp. 198–206, 1995. View at Google Scholar · View at Scopus
  35. C. H. Jones, C. G. Newstead, E. J. Wills, and A. M. Davison, “Serum albumin and survival in CAPD patients: the implications of concentration trends over time,” Nephrology Dialysis Transplantation, vol. 12, no. 3, pp. 554–558, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. P. G. Blake, G. Flowerdew, R. M. Blake, and D. G. Oreopoulos, “Serum albumin in patients on continuous ambulatory peritoneal dialysis—predictors and correlations with outcomes,” Journal of the American Society of Nephrology, vol. 3, no. 8, pp. 1501–1507, 1993. View at Google Scholar · View at Scopus
  37. S. H. Chung, B. Lindholm, and H. B. Lee, “Is malnutrition an independent predictor of mortality in peritoneal dialysis patients?” Nephrology Dialysis Transplantation, vol. 18, no. 10, pp. 2134–2140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Noh, S. W. Lee, S. W. Kang et al., “Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients,” Peritoneal Dialysis International, vol. 18, no. 4, pp. 387–394, 1998. View at Google Scholar · View at Scopus
  39. C. Suzuki, S. Nakamura, H. Ishibashi-Ueda, F. Yoshihara, and Y. Kawano, “Evidence for severe atherosclerotic changes in chronic hemodialysis patients: comparative autopsy study against cardiovascular disease patients without chronic kidney disease,” Therapeutic Apheresis and Dialysis, vol. 15, no. 1, pp. 51–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. K. L. Adeney, D. S. Siscovick, J. H. Ix et al., “Association of serum phosphate with vascular and valvular calcification in moderate CKD,” Journal of the American Society of Nephrology, vol. 20, no. 2, pp. 381–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. W. Y. Qunibi, “Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD),” Kidney International, Supplement, vol. 66, no. 90, pp. S8–S12, 2004. View at Google Scholar · View at Scopus
  42. G. A. Block, T. E. Hulbert-Shearon, N. W. Levin, and F. K. Port, “Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study,” American Journal of Kidney Diseases, vol. 31, no. 4, pp. 607–617, 1998. View at Google Scholar · View at Scopus
  43. M. Litwin, E. Wühl, C. Jourdan et al., “Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1494–1500, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. M. M. Mitsnefes, T. R. Kimball, J. Kartal et al., “Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism,” Journal of the American Society of Nephrology, vol. 16, no. 9, pp. 2796–2803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Saygili, Ö. Barutçu, N. Cengiz et al., “Carotid intima media thickness and left ventricular changes in children with end-stage renal disease,” Transplantation Proceedings, vol. 34, no. 6, pp. 2073–2075, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Covic, N. Mardare, P. Gusbeth-Tatomir et al., “Increased arterial stiffness in children on haemodialysis,” Nephrology Dialysis Transplantation, vol. 21, no. 3, pp. 729–735, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Blacher, M. E. Safar, A. P. Guerin, B. Pannier, S. J. Marchais, and G. M. London, “Aortic pulse wave velocity index and mortality in end-stage renal disease,” Kidney International, vol. 63, no. 5, pp. 1852–1860, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. R. C. Shroff, A. E. Donald, M. P. Hiorns et al., “Mineral metabolism and vascular damage in children on dialysis,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2996–3003, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Ketteler, P. Bongartz, R. Westenfeld et al., “Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study,” The Lancet, vol. 361, no. 9360, pp. 827–833, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Honda, A. R. Qureshi, O. Heimbürger et al., “Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD,” American Journal of Kidney Diseases, vol. 47, no. 1, pp. 139–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Stenvinkel, K. Wang, A. R. Qureshi et al., “Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin,” Kidney International, vol. 67, no. 6, pp. 2383–2392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Nicastro, A. Schnider, and B. Leemann, “Iron-deficiency anemia as a rare cause of cerebral venous thrombosis and pulmonary embolism,” Case Reports in Medicine, vol. 2012, Article ID 497814, 3 pages, 2012. View at Publisher · View at Google Scholar
  53. D. S. Hartfield, N. J. Lowry, D. L. Keene, and J. Y. Yager, “Iron deficiency: a cause of stroke in infants and children,” Pediatric Neurology, vol. 16, no. 1, pp. 50–53, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Locatelli, R. L. Pisoni, C. Combe et al., “Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS),” Nephrology Dialysis Transplantation, vol. 19, no. 6, pp. 121–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. P. T. Vlagopoulos, H. Tighiouart, D. E. Weiner et al., “Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease,” Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3403–3410, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Messana, C.-C. Chuang, M. Turenne et al., “Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model,” American Journal of Kidney Diseases, vol. 53, no. 3, pp. 503–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Rossert, C. Gassmann-Mayer, D. Frei, and W. McClellan, “Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients,” Nephrology Dialysis Transplantation, vol. 22, no. 3, pp. 794–800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. J. M. López-Gómez, J. M. Portolés, and P. Aljama, “Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality,” Kidney International Supplements, vol. 111, pp. S75–S81, 2008. View at Google Scholar
  59. A. T. Kausz, C. Solid, B. J. G. Pereira, A. J. Collins, and W. St. Peter, “Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?” American Journal of Kidney Diseases, vol. 45, no. 1, pp. 136–147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. L. A. Szczech, H. X. Barnhart, J. K. Inrig et al., “Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes,” Kidney International, vol. 74, no. 6, pp. 791–798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Minutolo, G. Conte, B. Cianciaruso et al., “Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in nondialysis CKD patients,” Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2880–2886, 2012. View at Publisher · View at Google Scholar
  62. R. D. Kilpatrick, C. W. Critchlow, S. Fishbane et al., “Greater Epoetin alfa responsiveness is associated with improved survival in hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 4, pp. 1077–1083, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Icardi, E. Paoletti, L. De Nicola et al., “Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation,” Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1672–1679, 2013. View at Publisher · View at Google Scholar
  64. J. J. Carrero, J. Axelsson, S. Snaedal-Jonsdottir et al., “Low hemoglobin in prevalent HD patients is associated with higher inflammatory status: impact of variations in the gene encoding for interleukin-6,” in Proceedings of the American Society of Nephrology Congress, SA-PO30, 2006.
  65. T. Shinzato, K. Abe, A. Furusu et al., “Serum pro-hepcidin level and iron homeostasis in japanese dialysis patients with Erythropoietin (EPO)-resistant anemia,” Medical Science Monitor, vol. 14, no. 9, pp. CR431–CR437, 2008. View at Google Scholar · View at Scopus
  66. H. I. Feldman, S. Kobrin, and A. Wasserstein, “Hemodialysis vascular access morbidity,” Journal of the American Society of Nephrology, vol. 7, no. 4, pp. 523–535, 1996. View at Google Scholar · View at Scopus
  67. S. J. Schwab, “Vascular access for hemodialysis,” Kidney International, vol. 55, no. 5, pp. 2078–2090, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Grandaliano, A. Teutonico, A. Allegretti et al., “The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis,” Kidney International, vol. 64, no. 2, pp. 715–719, 2003. View at Publisher · View at Google Scholar · View at Scopus